Contact
searchSearch
HMP Global
Login

Q&As

Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
Michelle Martel, PhD
Q&As
When It Comes to ADHD in Women, There's Still So Much to Learn
10/31/2024
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares...
10/31/2024
Psych Congress Network
Andrew Penn
Q&As
Psychedelics: New Research, Regulations, and Horizons
10/30/2024
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must...
10/30/2024
Psych Congress Network
Jo Hughes
Q&As
Unpacking the Pressing Challenges of Polypharmacy in Psychiatry
10/30/2024
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY,...
10/30/2024
Psych Congress Network
Beau Kilmer, PhD
Q&As
Psychedelic Policy and Market Considerations
10/28/2024
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the...
10/28/2024
Psych Congress Network
Dr Chepke
Q&As
How should clinicians choose one lithium formulation over another?
09/09/2024
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA,...
09/09/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
Bruce Fischer
Q&As
Family of Origin Psychotherapy in Addiction Treatment Creates ‘Beneficial Change,’ Expert Says
09/07/2024
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a...
09/07/2024
Psychiatry & Behavioral Health
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psychiatry & Behavioral Health
Lucia Cheng, MD
Q&As
How to Establish Better Virtual Patient Rapport
09/06/2024
Lucia Cheng, MD, offers clinical pearls for mental health clinicians practicing in a telehealth setting.
Lucia Cheng, MD, offers clinical pearls for mental health clinicians practicing in a telehealth setting.
Lucia Cheng, MD, offers clinical...
09/06/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use